- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on OSIRIS THERAPEUTICS (OSIR)
by latest | most commented
-
Adult Stem Cell Drugs and Therapies Are the Next Big Market
-
Stem Cell Index Surges in Past Week
-
Optimistic on Osiris Therapeutics
-
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
-
Banking on NeoStem
-
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
-
8 'Bathwater Babies' and 20 'Dogs with Fleas' Stocks for the Week
-
FDA and Clinical Trial Updates: Osiris Sees Flaw in Crohn's Disease Trial
-
Osiris Hits a Speedbump in Crohn's Program
-
With Funding Ban Lifted, Stem Cell Index Soars
-
12 Stem Cell Stocks - Updated
-
Know Your Options When Investing in Biotech Stocks
-
Osiris Therapeutics Enters a New Age of Pharma Risk and Profit Share
-
Little Rays of Sunshine in the Markets
-
Trading the Trials and FDA Decision Calendar
-
Stem Cell Research Stocks Soar as Obama Takes Office
-
20 Emerging Healthcare Stocks to Watch in '09
-
9 Possible Pharma Deals for 2009
-
Stem Cell and Regenerative Medicine Stocks Surge in December
-
Healthcare: Investing Trends for 2009
-
Cytori Therapeutics and Cypress Bio: Two Buys Based on Positive Trial Results
-
ETF Ideas Poised to Benefit from Pending Healthcare Reform
-
New Emerging Biotech and Pharma Company Index
-
Regenerative Medicine: Big Pharma's Next Frontier
-
ETFI Global Healthcare Sector PerfomIdex
-
Genzyme and Osiris Get Together on Stem Cells
-
Cosmetic and Reconstructive Medicine ETF Outpaces Healthcare Sector
-
Three Biotechs Hitting New 52-Week Highs
-
10 Biotechs in Stem Cells that Could Profit Under the Democrats
-
Osiris Therapeutics: Bone Regeneration = Big Bucks
-
How to Profit from Stem Cell R&D - Barron's
-
Osiris: Positive Heart Drug Data Boosts Stock
-
Biotech Day in Review: Biosite Takes $85 Offer from Beckman Coulter
-
Biotech Week In Review: Recovering Some Lost Ground
-
Russell 3000's Best and Worst Stocks, Week and Year to Date
-
Russell 3000's Best and Worst Stocks, Week and Year to Date
-
Osiris: Promising Stem Cell Research, Risky Management
-
Biotech Day In Review: Osiris Stem Cells Treatment Has Unexpected Results
-
Osiris: Knee Replacement Drug A Bust
-
Best Stem Cell Plays: Osiris and Aastrom
-
2007: The Year Of Biotech IPOs?